Cargando…

Stewardship Nightmare: Ceftolozane/Tazobactam–Resistant Pseudomonas aeruginosa Infections Accelerated by the COVID-19 Pandemic

Background: The Centers for Disease Control and Prevention reported 32,600 cases, 2,700 deaths, and healthcare costs of 767 million dollars attributed to multidrug-resistant Pseudomonas aeruginosa. A recent study of 128 patients with nosocomial pneumonia due to P. aeruginosa showed the noninferiorit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haviland, Adam, Weston, Gregory, Nori, Priya, Szymczak, Wendy, Guo, Yi, Marrero Rolon, Rebecca M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2021
Materias:	Mdr Gnr
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9551526/ http://dx.doi.org/10.1017/ash.2021.137

Ejemplares similares

Evaluation of Ceftolozane/Tazobactam, Ceftazidime/Avibactam and Meropenem/Vaborbactam Against Multidrug-Resistant (MDR) Pseudomonas
por: Shamsulddin, Haider, et al.
Publicado: (2021)

Management of Pseudomonas aeruginosa Bloodstream Infection and Impact on Health Outcomes
por: Ramanathan, Swetha, et al.
Publicado: (2021)

Pseudomonas aeruginosa bacteremia mortality and resistance trends in the Veterans’ Health Administration (VHA) system
por: Hojat, Leila, et al.
Publicado: (2022)

Difference in Susceptibility Between Carbapenemase- and Non–Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae
por: Clark, Justin, et al.
Publicado: (2021)

Time Above All Else: Pharmacodynamic Analysis of Β-Lactams in Critically Ill Patients
por: Landmesser, Katherine, et al.
Publicado: (2021)

Treatment of Extensively Drug-Resistant (XDR) Acinetobacter in US Veterans’ Affairs (VA) Medical Centers
por: Fitzpatrick, Margaret, et al.
Publicado: (2021)

How Does Antimicrobial Resistance Increase Medical Costs in Community-Acquired Acute Pyelonephritis?
por: Kim, Bongyoung, et al.
Publicado: (2021)

Inpatient point-prevalence screening of New Delhi Metallo-β-lactamase (NDM)–producing Enterobacaterales and Candida auris
por: Greco, Christian, et al.
Publicado: (2022)

Low function and frequent readmission in nursing home patients with persistent resistant gram-negative bacterial colonization
por: Mills, John, et al.
Publicado: (2022)

A retrospective longitudinal observational study of natural history of ESBL/MDR gram negative organisms in patients hospitalized in a tertiary hospital
por: Vasudeva, Shikha, et al.
Publicado: (2022)

Characteristics of patients positive for COVID-19 and multidrug-resistant organisms in Tennessee, 2020–2021
por: Stover, Carolyn, et al.
Publicado: (2022)

Characterization of carbapenem-resistant gram-negative bacteria collected in the Sentinel Surveillance Program, 2018–2019
por: Spicer, Lori, et al.
Publicado: (2022)

Predicting the regional impact of interventions to prevent and contain multidrug-resistant organisms
por: Cincotta, Samuel, et al.
Publicado: (2022)

Carbapenemase genes and mortality in patients with carbapenem-resistant Enterobacterales, Atlanta, Georgia, 2011–2020
por: Witt, Lucy, et al.
Publicado: (2023)

Colonization with extended-spectrum cephalosporin-resistant Enterobacterales (ESCrE) in hospitalized patients in Botswana
por: Mannathoko, Naledi Betsi, et al.
Publicado: (2023)

Whole-genome sequencing of carbapenem-resistant Enterobacterales isolates and evaluation of hospital-acquired infections
por: Ajaka, Leama, et al.
Publicado: (2023)

Real-world clinical outcomes of cefiderocol therapy in the Veterans Health Administration, 2019–2022
por: Amenta, Eva, et al.
Publicado: (2023)

Carbapenem-resistant Enterobacterales susceptibility patterns to new antimicrobials: A single-center analysis
por: Monk, Miranda, et al.
Publicado: (2023)

Identifying patients at high risk for carbapenem-resistant Enterobacterales carriage upon admission to acute-care hospitals
por: Howard-Anderson, Jessica, et al.
Publicado: (2023)

Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa
por: Barnes, Melissa D., et al.
Publicado: (2018)

Ceftolozane/Tazobactam Dosing Requirements Against Pseudomonas aeruginosa Bacteremia
por: Ruiz, Jesus, et al.
Publicado: (2020)

Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa
por: Teo, Jocelyn Qi-Min, et al.
Publicado: (2021)

Ceftolozane–tazobactam- and ceftazidime–avibactam-resistant Pseudomonas aeruginosa mastoiditis
por: Jacobs, Jeremy, et al.
Publicado: (2020)

Ceftolozane/tazobactam heteroresistance in cystic fibrosis-related Pseudomonas aeruginosa infections
por: Monogue, Marguerite L, et al.
Publicado: (2023)

1317. Prevalence of Pseudomonas aeruginosa as the Causative Organism for Community Acquired Pneumonia
por: Haviland, Adam D, et al.
Publicado: (2021)

Ceftolozane-tazobactam for the Treatment of Multi Drug-resistant Pseudomonas aeruginosa (MDRPA) Infections
por: Molnar, Esther, et al.
Publicado: (2017)

1222. Ceftolozane-Tazobactam Heteroresistance in Cystic Fibrosis Related Pseudomonas aeruginosa Infections
por: Sanders, James, et al.
Publicado: (2021)

415 In Vitro Potency of Ceftolozane/Tazobactam against Pseudomonas aeruginosa Displaying Multidrug Resistance
por: Sutherland, Christina, et al.
Publicado: (2014)

292. Ceftolozane/Tazobactam for Treatment of Osteomyelitis due to Multi-Drug-Resistant Pseudomonas aeruginosa
por: Gerlach, Anthony, et al.
Publicado: (2018)

Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study
por: Gallagher, Jason C, et al.
Publicado: (2018)

2291. Evaluation of Multidrug-Resistant Pseudomonas aeruginosa Isolates in Patients Receiving Ceftolozane/tazobactam
por: Bodo, Emily C, et al.
Publicado: (2019)

349. Hardware-Associated Multidrug-resistant Pseudomonas aeruginosa Meningitis Treated with Ceftolozane-Tazobactam
por: Li, Caitlin, et al.
Publicado: (2020)

Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant Pseudomonas aeruginosa Infections in Neutropenic Patients
por: Coppola, Paolo E., et al.
Publicado: (2020)

Cefiderocol Activity Against Clinical Pseudomonas aeruginosa Isolates Exhibiting Ceftolozane-Tazobactam Resistance
por: Simner, Patricia J, et al.
Publicado: (2021)

Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa
por: Gill, Christian M, et al.
Publicado: (2022)

Activity of Ceftolozane-Tazobactam Against Global Pseudomonas Aeruginosa and Non-Susceptible Phenotypes: SMART 2016
por: Lob, Sibylle, et al.
Publicado: (2017)

Ceftolozane-Tazobactam Resistance in Multidrug-Resistant Pseudomonas aeruginosa Isolates Not Associated with AmpC Activity
por: Tran, Truc T, et al.
Publicado: (2017)

Postoperative soft-tissue infection due to multidrug-resistant Pseudomonas aeruginosa: usefulness of ceftolozane-tazobactam
por: Monterrubio-Villar, Jesús, et al.
Publicado: (2018)

Experience With Ceftolozane-Tazobactam for the Treatment of Serious Pseudomonas aeruginosa Infections in Saudi Tertiary Care Center
por: Bosaeed, M, et al.
Publicado: (2020)

1592. In Vitro Activity of Ceftolozane/Tazobactam (C/T) Against Enterobacteriaceae and Pseudomonas aeruginosa Circulating in Chile
por: Rivas, Lina M, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cdnjvvkdumnctg30bc79em2r0u